Intensified chemotherapy for diffuse large B-cell lymphomas

The Lancet

Volumn 378, Issue 9806, 2011, Pages 1828-1829

  Vose, Julie M ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINATE CALCIUM; IFOSFAMIDE; LENALIDOMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL PRACTICE; DRUG TOLERABILITY; EVENT FREE SURVIVAL; GENE EXPRESSION PROFILING; GERMINAL CENTER; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; INTRACELLULAR SIGNALING; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NOTE; ONCOGENE MYC; ONCOLOGICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL;

EID: 82255164025     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61269-5     Document Type: Note

References (11)

1. C Récher, B Coiffier, C Haioun for the Groupe d'Etude des Lymphomes de l'Adulte Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial Lancet 378 2011 1858 1867
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med 329 1993 987 994
3. M Pfreundschuh, L Trumper, A Osterborg et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 2006 379 391
4. H Tilly, E Lepage, B Coiffier et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma Blood 102 2003 4284 4289 (Pubitemid 37494085)
5. A Rosenwald, G Wright, WC Chan et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma N Engl J Med 346 2002 1937 1947 (Pubitemid 34651353)
6. SM Aukema, R Siebert, E Schuuring et al. Double-hit B-cell lymphomas Blood 117 2011 2319 2331
7. RO Casasnovas, M Meignan, A Berriolo-Riedinger et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma Blood 118 2011 37 43
8. GS Nowakowski, B Laplant, TM Habermann et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study Leukemia 2011 10.1038/leu.2011.165 published online July 1.
9. J Ruan, P Martin, RR Furman et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma J Clin Oncol 29 2010 690 697
10. RH Advani, JP Sharman, SM Smith et al. The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (pts) with relapsed/refractory B cell malignancies: final results from a phase I study Ann Oncol 22 suppl 4 2011 iv135 iv137
11. WH Wilson, K Dunleavy, S Pitaluga et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers J Clin Oncol 26 2008 2717 2724